Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme

Journal of Clinical Oncology

Volumn 18, Issue 7, 2000, Pages 1481-1491

  Osoba, David ^a   Brada, M ^a   Yung, W K A ^a   Prados, M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROCARBAZINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; COMMUNICATION DISORDER; DISEASE COURSE; DROWSINESS; FEMALE; FUNCTIONAL ASSESSMENT; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; VISUAL DISORDER;

EID: 0034034511     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.7.1481     Document Type: Article

References (20)

1. Mackworth N, Fobair P, Prados MD: Quality of life self-reports from 100 brain tumor patients: Comparisons with Karnofsky Performance Scores. J Neurooncol 14:243-253, 1992
2. Weitzner MA, Meyers CA, Gelke CK, et al: The Functional Assessment of Cancer Therapy (FACT) Scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151-1161, 1995
3. Osoba D, Aaronson NK, Muller M, et al: Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 31:263-278, 1997
4. Brada M, Yung WKA, Osoba D: Symptom burden in patients (pts) with recurrent high-grade gliomas. Proc Am Soc Clin Oncol 18:147a, 1999 (abstr 564)
5. Osoba D, Aaronson NK, Zee B, et al: Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Qual Life Res 6:103-108, 1997
6. Aaronson NK, Ahmedzai S, Bullinger M, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst 85:365-376, 1993
7. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364, 1994
8. Ringdal GI, Ringdal K: Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogenous diagnoses. Qual Life Res 2:129-140, 1993
9. Niezgoda HE, Pater JL: A validation study of the domains of the core EORTC Quality of Life Questionnaire. Qual Life Res 2:319-325, 1993
10. Osoba D, Aaronson NK, Muller K, et al: The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5:139-150, 1996
11. Osoba D: Approaches to assessing health-related quality of life in clinical trials for patients with high-grade recurrent gliomas. Qual Life Res 6:695, 1997 (abstr 274)
12. Yung A, Levin VA, Albright A, et al: Randomized trial of Temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc Am Soc Clin Oncol 18:139a, 1999 (abstr 532)
13. Fayers P, Aaronson N, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual. Brussels, Belgium, Quality of Life Unit, European Organization for Research and Treatment of Cancer Data Centre, 1995
14. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life-scores. J Clin Oncol 16:139-144, 1998
15. King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555-567, 1996
16. Ware JE, Kosinski M, Keller SD: SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA, The Health Institute, New England Medical Center, 1994
17. Jaeschke R, Singer J, Guyatt GH: Measurement of health status: Ascertaining the minimal clinically important difference. Control Clin Trials 10:407-415, 1989
18. Juniper EF, Guyatt GH, Willan A, et al: Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 47:81-87, 1994
19. Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting changes in health status. Med Care 27:S178-S189, 1989 (suppl 3)
20. Cohen J: Statistical Power Analysis for the Behavioural Sciences. New York, NY, Academic Press, 1977